Compare FF & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FF | OVID |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.5M | 117.3M |
| IPO Year | N/A | 2017 |
| Metric | FF | OVID |
|---|---|---|
| Price | $3.46 | $1.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 204.0K | ★ 1.7M |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | ★ 6.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $137,409,000.00 | $6,610,000.00 |
| Revenue This Year | N/A | $1,077.56 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 945.89 |
| 52 Week Low | $3.09 | $0.24 |
| 52 Week High | $5.78 | $2.01 |
| Indicator | FF | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 52.76 | 57.39 |
| Support Level | $3.15 | $1.54 |
| Resistance Level | $3.44 | $1.75 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 92.21 | 71.20 |
FutureFuel Corp makes and sells diversified chemical products, bio-based fuel products, and specialty chemical products. The company is organized into two segments based on product type: biofuels and chemicals. The biofuel segment sells biodiesel and other petroleum products. Its fuels are made from a mix of diesel, vegetable oils, and grease feedstock. The chemicals segment sells products that are used in the production of agricultural chemicals, which include herbicides, coatings, and cleaning products, such as detergents.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.